



Synergistic effects of vagus nerve stimulation and antiseizure medication

Yaroslav Winter^{1,2} · Katharina Sandner¹ · Martin Glaser³ · Dumitru Ciolac⁴ · Viktoria Sauer² · Andreas Ziebart⁵ · Ali Karakoyun⁵ · Vitalie Chiosa⁷ · Assel Saryyeva⁶ · Joachim Krauss⁶ · Florian Ringel³ · Sergiu Groppa⁴

Received: 30 March 2023 / Revised: 13 June 2023 / Accepted: 13 June 2023 / Published online: 27 June 2023
© The Author(s) 2023

Abstract

Introduction Vagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures. Until now, favorable combinations of different groups of antiseizure medication (ASM) and VNS have not been sufficiently addressed. The aim of this study was to identify the synergistic effects between VNS and different ASMs.

Methods We performed an observational study of patients with epilepsy who were implanted with VNS and had a stable ASM therapy during the first 2 years after the VNS implantation. Data were collected from the Mainz Epilepsy Registry. The efficacy of VNS depending on the concomitantly used ASM group/individual ASMs was assessed by quantifying the responder rate ($\geq 50\%$ seizure reduction compared to the time of VNS implantation) and seizure freedom (absence of seizures during the last 6 months of the observation period).

Results One hundred fifty one patients (mean age 45.2 ± 17.0 years, 78 females) were included in the study. Regardless of the used ASM, the responder rate in the whole cohort was 50.3% and the seizure freedom was 13.9%. Multiple regression analysis showed that combination of VNS with synaptic vesicle glycoprotein (SV2A) modulators (responder rate 64.0%, seizure freedom 19.8%) or slow sodium channel inhibitors (responder rate 61.8%, seizure freedom 19.7%) was associated with a statistically significant better responder rate and seizure freedom than combinations of VNS and ASM with other mechanism of action. Within these ASM groups, brivaracetam showed a more favorable effect than levetiracetam, whereas lacosamide and eslicarbazepine were comparable in their effects.

Conclusion Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.

Keywords Epilepsy · Vagus nerve stimulation · Antiseizure medication · Synergistic effects

✉ Yaroslav Winter
yaroslav.winter@unimedizin-mainz.de

¹ Department of Neurology, Mainz Comprehensive Epilepsy and Sleep Medicine Center, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr 1, 55131 Mainz, Germany

² Department of Neurology, Philipps-University, Marburg, Germany

³ Department of Neurosurgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

⁴ Department of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

⁵ Department of Neurosurgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany

⁶ Department of Neurosurgery, Medical School Hannover, MHH, Hannover, Germany

⁷ Laboratory of Neurobiology and Medical Genetics, Department of Neurology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova

Abbreviations

AMPA	α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ASM	Antiseizure medication
CA	Carboanhydrase
EEG	Electroencephalography
GABA	Gamma-aminobutyric acid
MAINZ-EPIREG	Mainz Epilepsy Registry
SV2A	Synaptic vesicle glycoprotein 2A
VNS	Vagus nerve stimulation

Introduction

Vagus nerve stimulation (VNS) is an effective, non-pharmacological therapy for epileptic seizures [9, 10, 24, 26, 27, 31]. Several studies have already demonstrated the effectiveness of VNS in reducing the frequency of epileptic seizures with responder rates varying between 33 and 89% [5, 8, 13, 14, 23]. Despite the numerous and increasingly available pharmacological and non-pharmacological treatment options for patients with epilepsy, there are still many patients with persistent seizures and refractory epilepsy, which could benefit from neurostimulation [17, 25]. Since VNS is approved only as an adjunctive therapy for epilepsy treatment, all patients with VNS also receive antiseizure medication (ASM). As the number of epilepsy patients benefiting from VNS increases, it is still unclear which ASMs work in a synergistic manner with this type of neurostimulation. While the rational combination of different ASMs was an objective of previous research, the favorable effects of ASM in combination with VNS were beyond its scope [28]. The identification of ASMs having synergetic effects with VNS is of major importance. This finding would improve treatment response, reduce adverse effects, and increase the quality of life in patients with epilepsy [22, 32]. In addition, VNS could potentially reduce behavioral adverse effects of ASM due to its mood improving properties. Effectively, the knowledge of synergetic effects of VNS with a specific mechanism of action of ASM will optimize the therapeutic response and reduce the side effects of epilepsy treatment.

The aim of this study was to identify the favorable combinations of VNS and ASMs in terms of their efficacy.

Methods

Study design and clinical evaluation

In this observational study, we included patients with epilepsy who were implanted with VNS and did not change their ASM during the 2 years after the implantation. All patients were treated at the Comprehensive Epilepsy and

Sleep Medicine Center, Germany, which is integrated into the Department of Neurology of the University Medical Center of the Johannes Gutenberg University Mainz, Germany. Implantation of VNS was performed in the neurosurgical departments of the three German university hospitals—University Medical Center Mainz, University Hospital Mannheim and Medical School Hannover. VNS implantation and post-operative management was carried out according to standard of care procedures. Data of the patients were retrieved from the Mainz Epilepsy Registry (MAINZ-EPIREG), which is focused on prospective evaluation of the disease course of patients with epilepsy. In order to estimate the combined efficacy of different ASMs and VNS, responder rate and seizure freedom were estimated for separate ASM groups. Responder rate was defined as the reduction in seizure frequency $\geq 50\%$ per month compared to the time of VNS implantation. Seizure freedom was defined as the absence of seizures during the last 6 months of the observation period. The monthly seizure frequency at the study onset was calculated considering the 6 months preceding the implantation of VNS. The monthly seizure frequency at the end of the second year after the implantation of VNS was calculated considering the last 6 months of the observation period. The seizure frequency was recorded in a systematic way before the implantation of VNS and during the whole study period by means of standardized patients' diaries. This study was approved by the local ethics committee and all of the patients have signed informed consent for participation in this study.

Statistics

Statistical analysis was performed using IBM SPSS Statistics Version 23.0 (IBM Corp., Armonk, NY, USA). The Kolmogorov–Smirnov test was used to assess the distribution of data. Variables are presented as mean, standard deviation (SD) and range. A t-test or analysis of variance was applied for group comparisons of normally distributed variables. For non-normal distribution, the Mann–Whitney U-test (two independent groups) or the Kruskal–Wallis test (more than two independent groups) was used. Statistical significance was set to a p-value of < 0.05 . Multiple regression analysis was performed to identify the independent factors that determine the responder rate and seizure freedom on stable therapy 2 years after VNS implantation.

Results

One hundred fifty one patients (mean age 45.2 ± 17.0 years, 78 females) with epilepsy and VNS were included in the study. The duration of epilepsy before the VNS implantation was on average 17.2 ± 11.6 years. Data on demographics

and clinical parameters are shown in Table 1. The following side effects due to VNS therapy were reported: postoperative pain in 13.9% of patients ($n=21$), which disappeared within 3 weeks after the implantation, coughing in 9.3% ($n=14$) of patients and hoarseness in 5.3% ($n=8$) of patients. There were no specific side effects reported due to the combination of VNS and ASMs. In our study population, 36 (23.8%) patients did not benefit from the VNS treatment, being similar to existing literature.

Regardless of the used ASMs, the overall observed responder rate was 50.3% and seizure freedom after 2 years following the VNS implantation was 13.9%.

Multiple regression analysis showed that combination of VNS with synaptic vesicle glycoprotein (SV2A) modulators or slow sodium channel inhibitors was associated with a statistically significant better responder rate and seizure freedom than combinations of VNS and ASM with other mechanism of action. This analysis considered demographic data (age and gender), number of ASM in

patient's history, type of epilepsy and activated autostimulation of VNS. In addition to specific mechanism of action, the lesser number of previous ASMs was an independent factor of better responder rate and seizure freedom in patients with VNS in our study (Table 2).

Table 3 shows the responder rates and seizure freedom according to combination of VNS with different mechanisms of action and different ASM. The concomitant use of synaptic vesicle glycoprotein 2A (SV2A) modulators (64.0%) and slow sodium channel inhibitors (61.8%) was associated with the best responder rate (64.0% and 61.8%, respectively) and the best seizure freedom (19.8% and 19.7%, respectively). Within the group of SV2A modulators, brivaracetam showed a more favorable responder rate of 69.2% and seizure freedom of 21.2% as compared to levetiracetam (53.8% and 15.4%, correspondingly, $p<0.05$). There was only a minor difference in responder rate and seizure freedom between eslicarbazepine and lacosamide (Table 3).

Table 1 Data on demographics and clinical parameters of patients with vagus nerve stimulation

	All patients ($n=151$)	Fast sodium channel inhibitors ($n=86$)	Slow sodium channel inhibitors ($n=76$)	SV2A modu- lators ($n=86$)	AMPA antagonists ($n=58$)	GABA ago- nists ($n=84$)	Calcium chan- nel inhibitors ($n=47$)	CA inhibitors ($n=56$)
Age, years								
Mean \pm SD (range)	45.2 \pm 17.0 (20–81)	44.6 \pm 17.4 (21–81)	46.9 \pm 17.3 (21–78)	44.7 \pm 18.12 (20–81)	42.0 \pm 16.7 (20–81)	43.1 \pm 16.3 (20–78)	44.6 \pm 16.9 (23–78)	44.6 \pm 17.5 (20–78)
Gender, n (%)								
Male	68 (45.0)	35 (43.2)	30 (42.3)	35 (42.2)	29 (52.7)	34 (43.0)	26 (56.5)	26 (50%)
Female	83 (55.0)	46 (56.8)	41 (57.7)	48 (57.8)	26 (47.3)	45 (57.0)	20 (43.5)	26 (50%)
VNS type, n (%)								
SenTiva®	56 (37.1)	31 (38.3)	25 (35.2)	36 (43.4)	23 (41.8)	20 (25.3)	15 (32.6)	13 (25.0)
AspireSR®	76 (50.3)	38 (46.9)	38 (53.5)	44 (53.0)	29 (52.7)	50 (63.3)	17 (37.0)	26 (50.0)
Demipulse®	6 (4.0)	5 (6.2)	4 (5.6)	1 (1.2)	2 (3.6)	5 (6.3)	4 (8.7)	4 (7.7)
VNS Ther- apy® pulse model 102	13 (8.6)	7 (8.6)	4 (5.6)	2 (2.4)	1 (1.8)	4 (5.1)	10 (21.7)	9 (17.3)
Duration of epilepsy before VNS, years								
Mean \pm SD (range)	17.2 \pm 11.6 (2.2–58.2)	18.9 \pm 12.2 (2.6–58.2)	16.4 \pm 11.5 (2.2–58.2)	16.4 \pm 10.1 (2.2–58.2)	17.6 \pm 11.4 (2.5–48.3)	16.5 \pm 10.3 (2.5–49.3)	16.8 \pm 11.83 (2.8–45.7)	15.9 \pm 12.2 (2.5–45.7)
Number of previous ASMs								
Mean \pm SD (range)	4 \pm 3 (0–14)	5 \pm 3 (0–11)	4 \pm 2 (1–9)	4 \pm 3 (1–11)	5 \pm 3 (1–11)	5 \pm 3 (0–14)	5 \pm 3 (0–14)	5 \pm 3 (0–14)

AMPA α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, CA carboanhydrase, GABA gamma-aminobutyric acid, SV2A synaptic vesicle glycoprotein 2A, VNS vagus nerve stimulation, SD standard deviation

Table 2 Multiple regression analysis of responder rate and seizure freedom in patients with vagus nerve stimulation

	Responder rate			Seizure freedom		
	B	95% CI	p-value	B	95% CI	p-value
Age	−0.01	−0.06; 0.04	0.71	0.01	−0.09; 0.51	0.18
Female gender	−0.06	−0.22; 0.09	0.43	0.08	−0.02; 0.19	0.12
Number of previous ASMs	−0.12	−0.24; −0.01	0.03	−0.01	−0.03; −0.01	0.04
Epilepsy type ^a	−0.05	−0.25; 0.08	0.41	−0.02	−0.13; 0.10	0.77
Autostimulation ^b	0.08	−0.19; 0.11	0.37	0.04	−0.11; 0.03	0.24
Fast sodium channel inhibitors	−0.92	−1.15; 0.12	0.58	−0.13	−0.24; 0.32	0.61
Slow sodium channel inhibitors	0.08	0.01; 0.11	0.03	0.09	0.01; 0.13	0.02
SV2A modulators	0.22	0.07; 0.36	<0.01	0.27	0.08; 0.54	<0.01
AMPA antagonists	−0.13	−2.82; 0.03	0.12	−0.02	−0.19; 0.11	0.81
GABA agonists	0.17	−0.08; 0.87	0.11	0.06	−0.11; 0.92	0.18
Calcium channel inhibitors	−0.35	−0.55; 0.14	0.49	−0.02	−0.19; 0.16	0.84
CA inhibitors	0.21	−0.04; 0.72	0.57	−0.23	−0.19; 0.14	0.78
Constant	0.51	−0.14; 0.89	0.21	0.20	−0.10; 0.50	0.18

^aGeneralized vs focal^bAutostimulation (on = 1, off = 2)

AMPA α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, B regression coefficient, CA carboanhydrase, CI confidence interval, GABA gamma-aminobutyric acid, SV2A synaptic vesicle glycoprotein 2A, VNS vagus nerve stimulation

Table 3 Responder rate and seizure freedom of patients with vagus nerve stimulation depending on the adjunctive ASMs

	Number of patients n (%)	Responder rate ^a n (%)	Seizure freedom n (%)
Substance group			
Fast sodium channel inhibitors	86 (57.0)	31 (36.0)	5 (5.8)
Slow sodium channel inhibitors	76 (50.3)	47 (61.8)	15 (19.7)
SV2A modulators	86 (57.0)	55 (64.0)	17 (19.8)
AMPA antagonists	58 (38.4)	22 (37.9)	5 (8.6)
GABA agonists	84 (55.6)	29 (34.5)	4 (4.8)
Calcium channel inhibitors	47 (31.1)	16 (34.0)	4 (8.5)
CA inhibitors	56 (37.1)	21 (37.5)	4 (7.1)
Adjunctive ASMs			
Valproate	41 (27.2)	13 (31.7)	1 (2.6)
Lamotrigine	64 (42.4)	23 (35.9)	4 (6.3)
Lacosamide	59 (39.1)	37 (62.7)	11 (18.6)
Levetiracetam	39 (25.8)	21 (53.8)	6 (15.4)
Brivaracetam	52 (34.4)	36 (69.2)	10 (21.2)
Carbamazepine	19 (12.6)	3 (15.8)	0 (0)
Eslicarbazepine	24 (15.9)	14 (58.3)	4 (16.7)
Oxcarbazepine	10 (6.6)	3 (30.0)	0 (0)
Topiramate	22 (14.6)	8 (36.4)	1 (4.5)
Zonisamide	39 (25.8)	13 (33.3)	4 (10.3)
Perampanel	39 (25.8)	14 (35.9)	4 (10.3)
Pregabalin	11 (7.3)	2 (18.2)	0 (0)
Clobazam	21 (13.9)	4 (19.0)	2 (9.5)
Ethosuximide	9 (6.0)	2 (22.2)	0 (0)
Phenobarbital	11 (7.3)	4 (36.4)	0 (0)

AMPA α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, CA carboanhydrase, GABA gamma-aminobutyric acid, SV2A synaptic vesicle glycoprotein 2A, VNS vagus nerve stimulation

^aResponder defined as a patient with a reduction in seizure frequency of $\geq 50\%$ compared to baseline

Discussion

Although VNS was established as an effective non-pharmacological therapy for patients with epilepsy decades ago, the evidence on favorable combinations of VNS and ASMs is limited. The responder rate and seizure freedom observed in our study population were similar to the data from previous reports [5, 8, 14, 26, 27]. Despite this, some of the previous studies showed a lower rate of seizure freedom [11]. This difference could be explained by the fact that we defined seizure freedom as absence of seizures during the last six months of the observation period compared to other studies that adopted a longer period for seizure freedom definition.

Overall, studies have identified several factors that could be beneficial for VNS therapy. It seems to be particularly effective in patients that have a shorter duration of epilepsy before the VNS implantation, in patients that predominantly experience generalized seizures and in those patients with a low seizure frequency before the implantation [1, 6, 7, 18]. However, the available evidence on factors associated with the improved outcome following VNS in the treatment of epilepsy is rather heterogeneous and has not yet addressed the synergistic effects of VNS and pharmacotherapy [1, 5]. Interestingly, there is growing evidence on synergistic effects of VNS and ketogenic diet showing that the seizure frequency is reduced more during their combination as compared to when either one is used alone [2].

Overall, VNS therapy reduces pharmacological burden, exhibits no interactions with ASM and favors the reduced costs of pharmacotherapy [16]. The knowledge regarding possible synergistic effects of VNS and ASMs would help to identify the most effective therapeutic combinations and improve the outcome in epilepsy patients. However, we have found only one study investigating the effects of combination of VNS with different ASMs. Labar et al. were following patients on different ASMs during the 12 month period after the VNS implantation [19]. The following ASMs were evaluated in this study: levetiracetam, zonisamide, oxcarbazepine, carbamazepine, lamotrigine, valproate, topiramate, and phenytoin [19]. Unfortunately, the authors could not find any favorable combination of ASM with VNS in this study [19]. The study was performed nearly a decade ago and ASMs that have showed positive effects in our analysis were not established at that time (except for levetiracetam). In addition, the observation of 12 months is quite a short time period for the estimation of VNS therapy. During the first year after the implantation, there is a need for titration and optimization of VNS parameters, so the therapeutic effects may vary. We chose a longer observational period of 24 months in order to estimate the effects of a stable VNS therapy.

The pathophysiological explanation of the possible synergistic effects between VNS and SV2A modulators remains unclear. On the cellular level of VNS mechanism of action, it has been shown that VNS mediates GABA-ergic, serotonergic and noradrenergic transmission [3, 4]. Hence, a synergistic effect between VNS and GABA-ergic ASMs would be expected. Our clinical data could not prove this assumption, suggesting that VNS could involve the same neural pathways as GABA-ergic medication, without providing any additional benefit in combination. Another known mechanism of action of VNS is desynchronization of electroencephalography (EEG) rhythms [29]. Interestingly, a similar desynchronizing effect has been shown for levetiracetam in an experimental setting [20, 21]. Therefore, it could be speculated that SV2A modulators work in a synergistic manner with VNS by amplifying the desynchronization of pathological EEG rhythms. Due to its higher affinity for SV2A, brivaracetam probably has a more prominent effect on EEG desynchronization than levetiracetam, however it should be investigated in future experimental studies [15]. It well is known that valproate, carbamazepine, and clonazepam can suppress neuronal hypersynchrony [20, 21]. However, in their study, Niespodziany et al. showed that levetiracetam is distinct from these classical ASMs by its selective effect on collective neuronal responses, rather than on single neuronal activities, suggesting a novel desynchronizing effect of this drug [21]. Perhaps, VNS may potentiate this specific desynchronizing effect of levetiracetam.

Another important finding of our work is the possible reduction and prevention of side effects of ASM polytherapy. It is known that sodium channel blockers given in high doses or in cases of their combination produce such side effects as dizziness, somnolence, vomiting and diplopia [12, 30, 33]. Considering the mechanism of action of sodium channel blockers, which showed to be favorable in combination with VNS, epileptologists can avoid higher doses or irrational combinations of sodium channel inhibitors. However, the prevention of pharmacological side effects was out of the scope of our study because we included patients on stable medication. Our findings would encourage further studies on the reduction of side effects of pharmacotherapy by employing an optimal combination of VNS and ASMs.

Among the limitations of this study was its observational design implying that the evidence could not be provided at the level of randomized control studies. The subgroups of patients treated with oxcarbazepine, pregabalin, ethosuximide and phenobarbital were small and should be addressed in larger studies. In addition, phenytoin, gabapentin, cannabidiol, fenfluramine and cenobamate were not included in this analysis and should also be considered in future studies. While phenytoin and gabapentin are old generation ASMs and are seldom prescribed for long-term therapy, cannabidiol and cenobamate are new generation

ASMs and their role in epilepsy treatment is a matter of increased interest. Also, we did not report the side effects of VNS in combination with ASMs in detail since we have not found any specific side effects due to the combination of VNS, and ASMs and only the side effects of VNS were reported. Next, in our study, we considered only patients who did not change their ASM after the VNS implantation that may constitute a selection bias. In our center, we motivate the patients not to change their ASM in first years after the VNS implantation by explaining that the improvement in seizure control occurs on a long-term. Nevertheless, we compared the clinical characteristics of patients excluded from the study due to changes in ASM (reduction or increase in number of ASM) with the study participants and did not find any significant differences in demographical or clinical (i.e. number of ASM or seizure frequency) parameters at study baseline, thereby mitigating the possibility of selection bias.

In conclusion, our data suggests that the combination of VNS with SV2A modulators or slow sodium channel inhibitors could be favorable to optimize seizure control. However, these findings should be investigated further under controlled conditions in order to provide a higher level of evidence.

Acknowledgements We would like to thank Kathleen Claussen for proofreading the manuscript.

Author contributions YW contributed to the conception, design of the study, acquisition and analysis of data and preparing the text; KS, MG, VS, AZ, AK, AS, JK and FR contributed to the acquisition and analysis of data and preparing the text; DC contributed to the preparing the text; SG contributed to the conception, design of the study and preparing the text.

Funding Open Access funding enabled and organized by Projekt DEAL.

Data availability Original data can be provided by the corresponding author on demand.

Declarations

Conflicts of interest YW received an unrestricted grant from UCB Pharma for medical writing assistance and statistical work. UCB was not involved in the study design; the collection, analysis, and interpretation of the data gathered; nor the writing of the study report or the manuscript. In addition, YW reports honoraria for educational presentations and consultations from Arvelle Therapeutics, Bayer AG, Bial, Eisai, LivaNova, Novartis and UCB Pharma. SG received compensation for professional services from Abbott, Abbvie, Bial, Medtronic, UCB and Zambon; research grants from Abbott, Boston Scientific, MagVenture, German Research Council and German Ministry of Education and Health. JK performed consultations for Medtronic and Boston Scientific. FR is a consultant for Stryker, Brainlab, Icotec and Spineart; and receives royalties from Spineart. MG received honoraria and educational grants from Precisis, LivaNova, Abbott, Medtronic, Boston Scientific and Nevro. KS, DC, AZ, AK, VC and AS declare no conflict of interest.

Ethical publication statement We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Abbasi M, Moghtadaie A, Miratashi Yazdi SA (2021) Factors affecting vagus nerve stimulation outcomes in epilepsy. *Neurol Res Int* 2021:9927311
2. Abdelmoity AT, Le Pichon JB, Abdelmoity SA, Sherman AK, Hall AS, Abdelmoity AT (2021) Combined use of the ketogenic diet and vagus nerve stimulation in pediatric drug-resistant epilepsy. *Epilepsia Open* 6:112–119
3. Austelle CW, O'Leary GH, Thompson S, Gruber E, Kahn A, Manett AJ, Short B, Badran BW (2022) A Comprehensive review of vagus nerve stimulation for depression. *Neuromodulation* 25:309–315
4. Broncel A, Bocian R, Kłos-Wojtczak P, Konopacki J (2019) GABAergic mediation of hippocampal theta rhythm induced by stimulation of the vagal nerve. *Brain Res Bull* 147:110–123
5. Chrastina J, Kocvarova J, Novak Z, Dolezalova I, Svoboda M, Brazdil M (2018) Older age and longer epilepsy duration do not predict worse seizure reduction outcome after vagus nerve stimulation. *J Neurol Surg A Cent Eur Neurosurg* 79:152–158
6. Englot DJ, Chang EF, Auguste KI (2011) Efficacy of vagus nerve stimulation for epilepsy by patient age, epilepsy duration, and seizure type. *Neurosurg Clin N Am* 22(443–448):v
7. Englot DJ, Rolston JD, Wright CW, Hassnain KH, Chang EF (2016) Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. *Neurosurgery* 79:345–353
8. García-Pallero MA, García-Navarrete E, Torres CV, Pastor J, Navas M, Sola RG (2017) Effectiveness of vagal nerve stimulation in medication-resistant epilepsy. Comparison between patients with and without medication changes. *Acta Neurochir (Wien)* 159:131–136
9. Giordano F, Zicca A, Barba C, Guerrini R, Genitori L (2017) Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity. *Epilepsia* 58(Suppl 1):85–90
10. González HFJ, Yengo-Kahn A, Englot DJ (2019) Vagus nerve stimulation for the treatment of epilepsy. *Neurosurg Clin N Am* 30:219–230
11. Halford JJ, Edwards JC (2020) Seizure freedom as an outcome in epilepsy treatment clinical trials. *Acta Neurol Scand* 142:91–107
12. Kanner AM, Bicchi MM (2022) Antiseizure medications for adults with epilepsy: a review. *JAMA* 327:1269–1281
13. Kavčič A, Kajdič N, Rener-Primec Z, Krajnc N, Žgur T (2019) Efficacy and tolerability of vagus nerve stimulation therapy (VNS) in Slovenian epilepsy patients: younger age and shorter

- duration of epilepsy might result in better outcome. *Acta Clin Croat* 58:255–264
14. Kawai K, Tanaka T, Baba H, Bunker M, Ikeda A, Inoue Y, Kameyama S, Kaneko S, Kato A, Nozawa T, Maruoka E, Osawa M, Otsuki T, Tsuji S, Watanabe E, Yamamoto T (2017) Outcome of vagus nerve stimulation for drug-resistant epilepsy: the first three years of a prospective Japanese registry. *Epileptic Disord* 19:327–338
 15. Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B (2016) Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. *Epilepsia* 57:538–548
 16. Kopciuch D, Barciszewska AM, Fliciniński J, Zaprutko T, Kus K, Steinborn B, Nowakowska E (2020) Analysis of pharmacotherapy regimen and costs in patients with drug-resistant epilepsy following vagus nerve stimulation therapy: a single-center study (Poland). *Acta Neurol Belg* 120:115–122
 17. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. *N Engl J Med* 342:314–319
 18. Labar D (2004) Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs. *Seizure* 13:392–398
 19. Labar DR (2002) Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. *Neurology* 59:S38–43
 20. Margineanu DG, Klitgaard H (2000) Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. *Pharmacol Res* 42:281–285
 21. Niespodziany I, Klitgaard H, Margineanu DG (2003) Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices. *NeuroReport* 14:1273–1276
 22. Panebianco M, Rigby A, Marson AG (2022) Vagus nerve stimulation for focal seizures. *Cochrane Database Syst Rev* 7:Cd002896
 23. Polkey CE, Nashef L, Queally C, Selway R, Valentin A (2022) Long-term outcome of vagus nerve stimulation for drug-resistant epilepsy using continuous assessment, with a note on mortality. *Seizure* 96:74–78
 24. Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L (2021) Neuromodulation in epilepsy: state-of-the-art approved therapies. *Lancet Neurol* 20:1038–1047
 25. Schulze-Bonhage A, Hirsch M, Knake S, Kaufmann E, Kegele J, Rademacher M, Vonck K, Coenen VA, Glaser M, Jenkner C, Winter Y, Groppa S (2023) Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials. *JAMA Neurol* 80:588
 26. Toffa DH, Touma L, El Mesquine T, Bouthillier A, Nguyen DK (2020) Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. *Seizure* 83:104–123
 27. Touma L, Dansereau B, Chan AY, Jetté N, Kwon CS, Braun KPJ, Friedman D, Jehi L, Rolston JD, Vadera S, Wong-Kisiel LC, Englot DJ, Keezer MR (2022) Neurostimulation in people with drug-resistant epilepsy: systematic review and meta-analysis from the ILAE Surgical Therapies Commission. *Epilepsia* 63:1314–1329
 28. Verrotti A, Tambucci R, Di Francesco L, Pavone P, Iapadre G, Altobelli E, Matricardi S, Farello G, Belcastro V (2020) The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. *Expert Rev Neurother* 20:167–173
 29. Wang H, Chen X, Lin Z, Shao Z, Sun B, Shen H, Liu L (2009) Long-term effect of vagus nerve stimulation on interictal epileptiform discharges in refractory epilepsy. *J Neurol Sci* 284:96–102
 30. Weissinger F, Losch F, Winter Y, Brecht S, Lendemans D, Kockelmann E (2019) Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: Results from a German prospective multicenter clinical practice study. *Epilepsy Behav* 101:106574
 31. Wheless JW, Gienapp AJ, Ryvlin P (2018) Vagus nerve stimulation (VNS) therapy update. *Epilepsy Behav* 88s:2–10
 32. Winter Y, Daneshkhan N, Galland N, Kotulla I, Krüger A, Groppa S (2018) Health-related quality of life in patients with poststroke epilepsy. *Epilepsy Behav* 80:303–306
 33. Winter Y, Sandner K, Vieth TL, Melzer N, Klimpe S, Meuth SG, Groppa S (2022) Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults: a prospective observational study. *CNS Drugs* 36:1113–1119